QIAcube Wins ALA New Product Award
QIAGEN earns highly distinguished prize of the automation industry for its new sample processing platform
VENLO, The Netherlands, February 2, 2007 - QIAGEN N.V., the worldwide leading provider of sample and assay technologies for life sciences, applied testing and molecular diagnostics, today announced that it has received the distinguished New Product Award (NPA) Designation of the Association for Laboratory Automation (ALA) for QIAcube, the company's revolutionary new platform for sample preparation. The award was presented on January 30 to QIAGEN at LabAutomation in Palm Springs, CA, the world's largest conference and exhibition on emerging and merging laboratory technologies, where QIAGEN officially introduced the QIAcube to the public on January 29.
The judges panel recognized the exceptional laboratory innovation and technology advancement of the QIAcube. With NPA Designation, ALA honors product entries less than one year old, using criteria in the following categories: market opportunity, impact on the field of laboratory automation and technology, extraordinary technical originality, and quality of supporting data. In the competition of twelve reviewed finalists, QIAcube was ranked one of the winners of the laboratory automation industry's most distinguished prize for new product entries.
"We are extremely pleased to have won this prestigious award in recognition of the revolutionary technology of the QIAcube and the new dimension of utility, which it creates for all users in molecular biology", said Wolfgang Leibinger, Global Business Director, Automated Systems for QIAGEN. "It also acknowledges the research and development accomplishments of our entire team and proves QIAGEN's leadership in innovative automation technology."
QIAcube is a compact platform incorporating novel and proprietary technologies that allows users to fully automate the processing of almost all QIAGEN consumable products that today are used manually in over 40,000 laboratories throughout the world. The extremely versatile, compact system in the low throughput range creates a new level of utility and opportunities to free up time, reduce costs, and increase performance for customers in any laboratory conducting molecular biology research in life science, applied testing and molecular diagnostics. The platform is priced at a fraction of current instrumentation products and was launched for use with up to 100 protocols which address almost any need in sample processing. The protocols are based on the identical QIAGEN consumable products used manually today - enabling fast and effortless migration of existing QIAGEN consumable users to the QIAcube.
- Target customers: Worldwide over 40,000 laboratories conducting molecular biology research in life science, applied testing and molecular diagnostics
- Applications: Low throughput (up to 12 samples per run) >100 spin-column based protocols for DNA, RNA, protein sample processing
- Developed by QIAGEN: includes proprietary technologies
- Size / weight: 65 cm (25.5 in) X 57 cm (22.4 in) X 62 cm (24.4 in) / 70.5 kg (155 lbs)
- More information on the QIAcube, images and video materials are available at www.qiagen.com/MyQIAcube.
QIAcube is intended for research use only. No claim of representation is intended for its use to provide information for the diagnosis, prevention or treatment of a disease.
The Association for Laboratory Automation (ALA) is a worldwide organization representing leaders in all aspects of laboratory automation. ALA seeks to provide a greater understanding of the importance and value of automation technologies in the laboratory setting, to advance the science and promote education related to laboratory automation by encouraging the study, advance the science and improving the practice of medical and laboratory automation. More information on ALA and the New Product Award Designation can be found at http://www.labautomation.org/.
QIAGEN N.V., a Netherlands holding company, is the leading provider of innovative sample and assay technologies and products. The products are considered standards in areas such as pre-analytical sample preparation and molecular diagnostics solutions. QIAGEN has developed a comprehensive portfolio of more than 500 proprietary, consumable products and automated solutions for sample collection, nucleic acid and protein handling, separation, and purification and open and target specific assays. The company's products are sold to academic research markets, to leading pharmaceutical and biotechnology companies, to applied testing customers (such as in forensics, veterinary, bio-defense and industrial applications) as well as to molecular diagnostics laboratories. QIAGEN employs more than 1,900 people worldwide. QIAGEN products are sold through a dedicated sales force and a global network of distributors in more than 40 countries. Further information about QIAGEN can be found at http://www.qiagen.com/.
Nicole York Dr. Thomas Theuringer
Manager Marketing Communications Manager Public Relations
Tel: +001 240 68 67660 Tel: 0049-2103-29-11826
Email: firstname.lastname@example.org Email: email@example.com